Developer docs
API playgroundTry for free, no card

Search company profiles

FirstWord Pharma

Full company profile

uuid000arcl

Namestring
FirstWord Pharma
Legal namestring
FirstWord
Websiteurl
firstwordpharma.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

FirstWord Pharma (legal entity: FirstWord) is a private B2B media business founded in 2005 and headquartered at 1140 Avenue of the Americas, New York. The company operates firstwordpharma.com, an online pharmaceutical industry news and analysis platform that aggregates, reports, and analyzes biopharma developments including FDA and EMA regulatory decisions, clinical trial results, M&A and deal activity, and major conference proceedings (BIO, ISTH, EAN, ISPNO). Editorial products include Top Stories, Conference News, and two proprietary research franchises — Physician Views Results surveys and KOL Views Preview — that capture primary physician sentiment and key opinion leader perspectives on emerging therapies.

The customer base is defined entirely at the persona level — pharmaceutical industry professionals, including healthcare practitioners, pharma executives, biotech researchers, and industry analysts — with no named enterprise customers, pricing disclosure, or ARR data in the source material. Distribution is exclusively digital and direct via the owned web property, with audience acquisition driven by SEO and organic search, supplemented by the recurring Friday Five newsletter. The company employs between 11 and 50 staff, operates without a mobile app, exposes no APIs, and has no disclosed parent company, investor base, ownership structure, or funding history in the available data. Christian Bisaillon is identified as CEO.

The business model is consistent with a niche specialty B2B trade publication: monetize enterprise readership (likely via subscription or sponsored-content arrangements, though pricing is not publicly disclosed) through differentiated editorial coverage and proprietary physician/KOL survey content. There is no indication of software-as-a-service products, platform technology, regulatory exposure, certifications, patents, or partnership ecosystems that would suggest a non-media revenue stream. The asset base is essentially editorial — brand, journalist relationships, conference access, and proprietary survey panels — rather than technology infrastructure.

Short descriptiontext

FirstWord Pharma is a private B2B media company that publishes pharmaceutical industry news, regulatory analysis, and conference coverage for pharma executives, biotech researchers, and healthcare professionals via its firstwordpharma.com website and proprietary physician survey products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical news, biopharma intelligence, clinical trial reporting, FDA regulatory updates, pharma industry analysis
NAICS code1 code
  • Newspaper, Periodical, Book, and Directory Publishers5131
SIC code1 code
  • Periodicals: Publishing Or Publishing & Printing2721
Product category
Pharmaceutical Industry Intelligence
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

FirstWord Pharma operates an online news and intelligence platform serving the global pharmaceutical industry. It aggregates, publishes, and analyzes biopharma industry developments including FDA decisions, clinical trial results, CHMP/EMA regulatory updates, M&A activity, conference coverage, physician sentiment surveys, and Key Opinion Leader (KOL) perspectives for healthcare professionals, pharma executives, and biotech researchers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

FirstWord Pharma is a pharmaceutical industry news and analysis platform that aggregates and reports on biopharma industry developments including FDA decisions, clinical trial results, regulatory updates, M&A activity, and conference news. The platform provides industry insights, analysis, and views including Physician Views Results and KOL (Key Opinion Leader) Views Preview. The site does not appear to offer distinct named product modules or a software platform offering - it functions as a content/news aggregation and analysis service for pharmaceutical industry professionals.

Product and service2 records
1FirstWord Pharma Industry News & Analysis Platform
CategoryIndustry News & Analysis
Description

The flagship web-based platform at firstwordpharma.com that delivers daily pharmaceutical industry news, FDA and EMA regulatory decision analysis, clinical trial updates, biopharma M&A coverage, and in-depth industry analysis for healthcare professionals, pharma executives, biotech researchers, and industry analysts.

2Friday Five Newsletter
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1FiercePharma
TypeDirect peer
Description

FiercePharma is a long-running pharma industry news publication covering drug commercialization, FDA decisions, clinical trials, and pharma marketing. It is a direct competitor for advertising and audience attention from pharma professionals.

2STAT News
TypeDirect peer
Description

STAT News delivers deep reporting on biotech, pharma, and health policy with a strong clinical-trial and FDA focus. It targets pharma executives, researchers, and clinicians—the same core audience FirstWord Pharma serves.

3Evaluate Pharma
TypeBroad incumbent
Description

Evaluate Pharma provides commercial intelligence, forecasts, and news for the pharma industry. It overlaps with FirstWord's news and analysis coverage but extends heavily into financial/forecast data products.

4BioCentury
TypeDirect peer
Description

BioCentury is a long-established biopharma intelligence publisher covering business, R&D, and policy. Its B2B subscription model and editorial depth directly parallel FirstWord's pharma intelligence positioning.

5BioPharma Dive
TypeDirect peer
Description

BioPharma Dive is a B2B publication providing news and analysis on the biotech and pharmaceutical industry, including drug development, regulatory policy, and industry trends. It serves the same pharma executive audience with similar editorial formats.

6Pharmaceutical Executive
TypeDirect peer
Description

Pharmaceutical Executive is a B2B publication covering pharma industry strategy, regulatory developments, and clinical research. It targets the same pharma executive and medical affairs audience with comparable editorial content.

7Drug Discovery & Development
TypeDirect peer
Description

Drug Discovery & Development covers pharma R&D, clinical trials, and emerging therapies. It is a comparable B2B publication serving researchers and pharma professionals with similar content verticals.

8Citeline / Pharma Intelligence (Informa)
TypeBroad incumbent
Description

Citeline (formerly Pharma Intelligence, part of Informa) is a major incumbent pharma intelligence provider offering news, analysis, and data products including Pink Sheet and TrialScope. It competes more broadly across pharma news and data intelligence.

9Endpoints News
TypeDirect peer
Description

Endpoints News is a daily biotech and pharmaceutical industry news outlet covering R&D, clinical trials, regulatory decisions, and M&A. It directly competes with FirstWord Pharma for the same pharma professional audience on overlapping beats including FDA decisions and clinical readouts.

10Pharma Times
TypeDirect peer
Description

Pharma Times is a UK-based pharma industry news outlet covering pipeline developments, regulatory news, and industry analysis. It targets a similar pharma professional audience with overlapping editorial beats.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FirstWord Pharma

Pharmaceutical Industry Intelligencefirstwordpharma.com

FirstWord Pharma is a private B2B media company that publishes pharmaceutical industry news, regulatory analysis, and conference coverage for pharma executives, biotech researchers, and healthcare professionals via its firstwordpharma.com website and proprietary physician survey products.

What FirstWord Pharma does

FirstWord Pharma (legal entity: FirstWord) is a private B2B media business founded in 2005 and headquartered at 1140 Avenue of the Americas, New York. The company operates firstwordpharma.com, an online pharmaceutical industry news and analysis platform that aggregates, reports, and analyzes biopharma developments including FDA and EMA regulatory decisions, clinical trial results, M&A and deal activity, and major conference proceedings (BIO, ISTH, EAN, ISPNO). Editorial products include Top Stories, Conference News, and two proprietary research franchises — Physician Views Results surveys and KOL Views Preview — that capture primary physician sentiment and key opinion leader perspectives on emerging therapies.

The customer base is defined entirely at the persona level — pharmaceutical industry professionals, including healthcare practitioners, pharma executives, biotech researchers, and industry analysts — with no named enterprise customers, pricing disclosure, or ARR data in the source material. Distribution is exclusively digital and direct via the owned web property, with audience acquisition driven by SEO and organic search, supplemented by the recurring Friday Five newsletter. The company employs between 11 and 50 staff, operates without a mobile app, exposes no APIs, and has no disclosed parent company, investor base, ownership structure, or funding history in the available data. Christian Bisaillon is identified as CEO.

The business model is consistent with a niche specialty B2B trade publication: monetize enterprise readership (likely via subscription or sponsored-content arrangements, though pricing is not publicly disclosed) through differentiated editorial coverage and proprietary physician/KOL survey content. There is no indication of software-as-a-service products, platform technology, regulatory exposure, certifications, patents, or partnership ecosystems that would suggest a non-media revenue stream. The asset base is essentially editorial — brand, journalist relationships, conference access, and proprietary survey panels — rather than technology infrastructure.

FirstWord Pharma firmographics

Firmographics
Name
FirstWord Pharma
Legal name
FirstWord
Website
https://firstwordpharma.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
FirstWord Pharma is a private B2B media company that publishes pharmaceutical industry news, regulatory analysis, and conference coverage for pharma executives, biotech researchers, and healthcare professionals via its firstwordpharma.com website and proprietary physician survey products.
Ownership category
akta.pro rank

Where FirstWord Pharma is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

FirstWord Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels3 records

FirstWord Pharma product offering

Product offering

Core offering

FirstWord Pharma operates an online news and intelligence platform serving the global pharmaceutical industry. It aggregates, publishes, and analyzes biopharma industry developments including FDA decisions, clinical trial results, CHMP/EMA regulatory updates, M&A activity, conference coverage, physician sentiment surveys, and Key Opinion Leader (KOL) perspectives for healthcare professionals, pharma executives, and biotech researchers.

Product overview

FirstWord Pharma is a pharmaceutical industry news and analysis platform that aggregates and reports on biopharma industry developments including FDA decisions, clinical trial results, regulatory updates, M&A activity, and conference news. The platform provides industry insights, analysis, and views including Physician Views Results and KOL (Key Opinion Leader) Views Preview. The site does not appear to offer distinct named product modules or a software platform offering - it functions as a content/news aggregation and analysis service for pharmaceutical industry professionals.

Differentiator

Problem solved

Functional benefit

Products and services

  • FirstWord Pharma Industry News & Analysis Platform The flagship web-based platform at firstwordpharma.com that delivers daily pharmaceutical industry news, FDA and EMA regulatory decision analysis, clinical trial updates, biopharma M&A coverage, and in-depth industry analysis for healthcare professionals, pharma executives, biotech researchers, and industry analysts.
  • Friday Five Newsletter

Companies that use FirstWord Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

FirstWord Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

FirstWord Pharma partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights3 records

FirstWord Pharma competitors and assessment

Company assessment

Direct peers

  • FiercePharma: FiercePharma is a long-running pharma industry news publication covering drug commercialization, FDA decisions, clinical trials, and pharma marketing. It is a direct competitor for advertising and audience attention from pharma professionals.
  • STAT News: STAT News delivers deep reporting on biotech, pharma, and health policy with a strong clinical-trial and FDA focus. It targets pharma executives, researchers, and clinicians—the same core audience FirstWord Pharma serves.
  • BioCentury: BioCentury is a long-established biopharma intelligence publisher covering business, R&D, and policy. Its B2B subscription model and editorial depth directly parallel FirstWord's pharma intelligence positioning.
  • BioPharma Dive: BioPharma Dive is a B2B publication providing news and analysis on the biotech and pharmaceutical industry, including drug development, regulatory policy, and industry trends. It serves the same pharma executive audience with similar editorial formats.
  • Pharmaceutical Executive: Pharmaceutical Executive is a B2B publication covering pharma industry strategy, regulatory developments, and clinical research. It targets the same pharma executive and medical affairs audience with comparable editorial content.
  • Drug Discovery & Development: Drug Discovery & Development covers pharma R&D, clinical trials, and emerging therapies. It is a comparable B2B publication serving researchers and pharma professionals with similar content verticals.
  • Endpoints News: Endpoints News is a daily biotech and pharmaceutical industry news outlet covering R&D, clinical trials, regulatory decisions, and M&A. It directly competes with FirstWord Pharma for the same pharma professional audience on overlapping beats including FDA decisions and clinical readouts.
  • Pharma Times: Pharma Times is a UK-based pharma industry news outlet covering pipeline developments, regulatory news, and industry analysis. It targets a similar pharma professional audience with overlapping editorial beats.

Broad incumbents

  • Evaluate Pharma: Evaluate Pharma provides commercial intelligence, forecasts, and news for the pharma industry. It overlaps with FirstWord's news and analysis coverage but extends heavily into financial/forecast data products.
  • Citeline / Pharma Intelligence (Informa): Citeline (formerly Pharma Intelligence, part of Informa) is a major incumbent pharma intelligence provider offering news, analysis, and data products including Pink Sheet and TrialScope. It competes more broadly across pharma news and data intelligence.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

FirstWord Pharma social profiles

Digital presence

FirstWord Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FirstWord Pharma leadership team

Management profile

Number of profiles

Profiles1 record

FirstWord Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FirstWord Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FirstWord Pharma

What does FirstWord Pharma do?

FirstWord Pharma operates an online news and intelligence platform serving the global pharmaceutical industry. It aggregates, publishes, and analyzes biopharma industry developments including FDA decisions, clinical trial results, CHMP/EMA regulatory updates, M&A activity, conference coverage, physician sentiment surveys, and Key Opinion Leader (KOL) perspectives for healthcare professionals, pharma executives, and biotech researchers.

When was FirstWord Pharma founded?

FirstWord Pharma was founded in 2004. It employs 51 to 100 people.

Where is FirstWord Pharma based?

FirstWord Pharma is headquartered in New York, United States, in the North America region.

Who are FirstWord Pharma's main competitors?

Direct peers on record are FiercePharma, STAT News, BioCentury, BioPharma Dive, Pharmaceutical Executive, Drug Discovery & Development, Endpoints News and Pharma Times. Broad incumbents are Evaluate Pharma and Citeline / Pharma Intelligence (Informa).

Does FirstWord Pharma have an API?

No public API is recorded for FirstWord Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireUlcerative Colitis: KOL InsightFirstWord Pharma published a report analyzing the market dynamics for ulcerative colitis treatments, gathering insights from key opinion leaders in North America and Europe regarding biosimilars and pipeline therapies. The analysis covers ten branded drugs and nine pipeline candidates, highlighting concerns over patent expirations, patient education on biosimilars, and the impact of safety and cost on prescribing habits.PR NewswireType 2 Diabetes Mellitus: KOL InsightFirstWord Pharma published a market research report titled 'Type 2 Diabetes: KOL Insight' based on interviews with 12 leading clinicians in the US and Europe. The report analyzes competitive dynamics, clinical benefits, and pricing pressures regarding various Type 2 Diabetes therapies including GLP-1 agonists, SGLT-2 inhibitors, and insulins. It highlights that differentiation remains difficult for new products and emphasizes the importance of efficacy, safety, and patient-friendly dosing in gaining market share.PR NewswireMedical Affairs Reputations (US): Type 2 Diabetes MellitusFirstWord Pharma is offering a market research report based on a survey of 100 U.S. physicians regarding the reputation and performance of Medical Affairs teams for ten leading Type 2 Diabetes Mellitus products. The study evaluates how these teams interact with healthcare providers, identifying strengths, weaknesses, and preferred communication methods across major pharmaceutical competitors. The report aims to help companies understand their standing relative to competitors in terms of physician engagement and value delivery.PR NewswireMedical Affairs Reputations (EU5): Type 2 Diabetes MellitusFirstWord Pharma conducted a survey of 150 physicians across Europe to evaluate the reputation and performance of Medical Affairs teams for ten leading Type 2 Diabetes Mellitus products. The resulting report analyzes which companies are leading or lagging in physician engagement and identifies key areas for improvement in medical affairs offerings. The study covers brands from major pharmaceutical firms including AstraZeneca, Boehringer Ingelheim, Eli Lilly, and others.